PT  - JOURNAL ARTICLE
AU  - Jerold Chun
AU  - Edward J. Goetzl
AU  - Timothy Hla
AU  - Yasuyuki Igarashi
AU  - Kevin R. Lynch
AU  - Wouter Moolenaar
AU  - Susan Pyne
AU  - Gabor Tigyi
TI  - International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature
AID  - 10.1124/pr.54.2.265
DP  - 2002 Jun 01
TA  - Pharmacological Reviews
PG  - 265--269
VI  - 54
IP  - 2
4099  - http://pharmrev.aspetjournals.org/content/54/2/265.short
4100  - http://pharmrev.aspetjournals.org/content/54/2/265.full
SO  - Pharmacol Rev2002 Jun 01; 54
AB  - The lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), are now recognized as important extracellular signaling molecules. These lipid mediators are pleiotropic; among the most common cellular responses are mitogenesis, cell survival (anti-apoptosis), inhibition of adenylyl cyclase and calcium mobilization. Physiologic events associated with these mediators include platelet aggregation, vasopressor activity, wound healing, immune modulation, and angiogenesis. Many of the actions of LPA and S1P are mediated through a set of eight G protein-coupled receptors. Five of these are S1P-prefering while the remaining three are LPA receptors. These receptors are expressed widely and in aggregate signal through a variety of heterotrimeric G proteins. The lysophospholipid receptor family is referred to commonly as the “Edg” group (e.g., Edg-1, Edg-2, etc.). Herein, the molecular pharmacology of the lysophospholipid receptors is reviewed briefly, and a rational nomenclature for LPA and S1P receptors that is consistent with the International Union of Pharmacology guidelines is proposed.